Abstracts tagged "outcome measures and pediatric medical center"

Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
Emily A. Smitherman¹, Bin Huang², Ronald M. Laxer³, C. April Bingham⁴, Cagri Yildirim-Toruner⁵, Beth Gottlieb⁶, Jennifer Weiss⁷, Tzielan Lee⁸, Sheetal S. Vora⁹, Jon (Sandy) Burnham¹⁰, Julia Harris¹¹, Judyann C. Olson¹², Mileka Gilbert¹³, Michelle Batthish¹⁴, Michael Shishov¹⁵, Dustin Fleck¹⁶ and Esi Morgan¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁶Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁹Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹Children's Mercy - Kansas City, Kansas City, MO, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Phoenix Children's Hospital, Phoenix, AZ, ¹⁶Pediatric Rheumatology, University of Michigan, Brighton, MI
Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].